Senti Selling General Administrative from 2010 to 2024

SNTI Stock  USD 2.16  0.02  0.93%   
Senti Biosciences' Selling General Administrative is increasing with slightly volatile movements from year to year. Selling General Administrative is predicted to flatten to about 25 M. For the period between 2010 and 2024, Senti Biosciences, Selling General Administrative quarterly trend regression had mean deviation of  8,983,409 and range of 33.5 M. View All Fundamentals
 
Selling General Administrative  
First Reported
2010-12-31
Previous Quarter
34.9 M
Current Value
25 M
Quarterly Volatility
11.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 4.7 M or Selling General Administrative of 25 M, as well as many indicators such as Price To Sales Ratio of 10.86, Dividend Yield of 0.0 or PTB Ratio of 0.42. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
  
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.

Latest Senti Biosciences' Selling General Administrative Growth Pattern

Below is the plot of the Selling General Administrative of Senti Biosciences over the last few years. It is Senti Biosciences' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Senti Biosciences' overall financial position and show how it may be relating to other accounts over time.
Selling General Administrative10 Years Trend
Slightly volatile
   Selling General Administrative   
       Timeline  

Senti Selling General Administrative Regression Statistics

Arithmetic Mean13,646,324
Geometric Mean10,808,054
Coefficient Of Variation82.93
Mean Deviation8,983,409
Median7,343,000
Standard Deviation11,317,088
Sample Variance128.1T
Range33.5M
R-Value0.73
Mean Square Error64.3T
R-Squared0.53
Significance0
Slope1,849,104
Total Sum of Squares1793.1T

Senti Selling General Administrative History

202425 M
202334.9 M
202240.8 M
202121.2 M
20209.3 M

About Senti Biosciences Financial Statements

Investors use fundamental indicators, such as Senti Biosciences' Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Senti Biosciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Selling General Administrative34.9 M25 M

Currently Active Assets on Macroaxis

When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(15.59)
Revenue Per Share
0.075
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.33)
Return On Equity
(1.11)
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.